Drotrecogin alfa (activated): does current evidence support treatment for any patients with severe sepsis?

Two international multicentre randomised controlled trials of drotrecogin alfa (activated) (DrotAA), the Recombinant Human Activated Protein C Worldwide Evaluation of Severe Sepsis (PROWESS) and Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) trials, have produc...

Descripción completa

Detalles Bibliográficos
Autores principales: Friedrich, Jan O, Adhikari, Neill KJ, Meade, Maureen O
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1550958/
https://www.ncbi.nlm.nih.gov/pubmed/16762040
http://dx.doi.org/10.1186/cc4947

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1550958/
https://www.ncbi.nlm.nih.gov/pubmed/16762040
http://dx.doi.org/10.1186/cc4947

Ejemplares similares